Patent Act of 1952 -- Patentable Subject Matter -- Ass'n for Molecular Pathology v. Myriad Genetics, Inc.

The article discusses the U.S. Supreme Court's ruling in the 2013 case Ass'n for Molecular Pathology v. Myriad Genetics Inc. which deals with the nation's Patent Act of 1952, patentable subject matter in the U.S., and biotechnology-related innovations. According to the article, the court determined...

Full description

Bibliographic Details
Published in:Harvard Law Review Vol. 127; no. 1; pp. 388 - 408
Format: Article
Published: Harvard Law Review Association Nov2013
Subjects:
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=hlh&AN=92509448&site=ehost-live
header:
  @attributes:
    shortDbName: hlh
    uiTerm: 92509448
    longDbName: Humanities International Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    jinfo:
      jid:
        0017811X
        HLR
      jtl: Harvard Law Review
      issn: 0017811X
      maglogo: N
    pubinfo:
      dt: Nov2013
      vid: 127
      iid: 1
      pid: 2349
      pub: Harvard Law Review Association
    artinfo:
      ui: 92509448
      ppf: 388
      ppct: 20
      formats:
      tig:
        atl: Patent Act of 1952 -- Patentable Subject Matter -- Ass'n for Molecular Pathology v. Myriad Genetics, Inc.
      aug:
      su:
        Association for Molecular Pathology v. Myriad Genetics Inc.
        Patentability -- Lawsuits & claims
        Molecules
        United States. Supreme Court
        Actions & defenses (Law)
        Patent law
        State statutes (United States)
        Biotechnology laws
        Law
        United States
      sug:
        subj:
          United States
          Association for Molecular Pathology v. Myriad Genetics Inc.
          Patentability -- Lawsuits & claims
          Molecules
          United States. Supreme Court
          Actions & defenses (Law)
          Patent law
          State statutes (United States)
          Biotechnology laws
          Law
      ab: The article discusses the U.S. Supreme Court's ruling in the 2013 case Ass'n for Molecular Pathology v. Myriad Genetics Inc. which deals with the nation's Patent Act of 1952, patentable subject matter in the U.S., and biotechnology-related innovations. According to the article, the court determined that molecules which are isolated from native DNA are not patent eligible, but certain molecules that are synthesized in a laboratory can be patented.
      pubtype: Academic Journal
      doctype: Article
      src: R
    language: English
    refInfo:
    copyright:
      @attributes:
        flag: Y
      dt:
        @attributes:
          year: 2013
    holdings:
      @attributes:
        islocal: N